Literature DB >> 17689347

Tobacco harm reduction: how rational public policy could transform a pandemic.

David Sweanor, Philip Alcabes, Ernest Drucker.   

Abstract

Nicotine, at the dosage levels smokers seek, is a relatively innocuous drug commonly delivered by a highly harmful device, cigarette smoke. An intensifying pandemic of disease caused or exacerbated by smoking demands more effective policy responses than the current one: demanding that nicotine users abstain. A pragmatic response to the smoking problem is blocked by moralistic campaigns masquerading as public health, by divisions within the community of opponents to present policy, and by the public-health professions antipathy to any tobacco-control endeavours other than smoking cessation. Yet, numerous alternative systems for nicotine delivery exist, many of them far safer than smoking. A pragmatic, public-health approach to tobacco control would recognize a continuum of risk and encourage nicotine users to move themselves down the risk spectrum by choosing safer alternatives to smoking--without demanding abstinence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689347     DOI: 10.1016/j.drugpo.2006.11.013

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  21 in total

Review 1.  Achieving appropriate regulations for electronic cigarettes.

Authors:  Daniela Saitta; Giancarlo Antonio Ferro; Riccardo Polosa
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

2.  Randomized within-subject trial to evaluate smokers' initial perceptions, subjective effects and nicotine delivery across six vaporized nicotine products.

Authors:  Natalie Voos; Lisa Kaiser; Martin C Mahoney; Clara M Bradizza; Lynn T Kozlowski; Neal L Benowitz; Richard J O'Connor; Maciej L Goniewicz
Journal:  Addiction       Date:  2019-04-25       Impact factor: 6.526

Review 3.  Tobacco and nicotine product testing.

Authors:  Dorothy K Hatsukami; Lois Biener; Scott J Leischow; Mitch R Zeller
Journal:  Nicotine Tob Res       Date:  2011-04-02       Impact factor: 4.244

4.  Harm reduction at the crossroads: the case of e-cigarettes.

Authors:  Wasim Maziak
Journal:  Am J Prev Med       Date:  2014-08-03       Impact factor: 5.043

5.  Whether to push or pull? Nicotine reduction and non-combusted alternatives - Two strategies for reducing smoking and improving public health.

Authors:  Tracy T Smith; Dorothy K Hatsukami; Neal L Benowitz; Suzanne M Colby; F Joseph McClernon; Andrew A Strasser; Jennifer W Tidey; Cassidy M White; Eric C Donny
Journal:  Prev Med       Date:  2018-03-29       Impact factor: 4.018

6.  Estimating demand for alternatives to cigarettes with online purchase tasks.

Authors:  Richard J O'Connor; Kristie M June; Maansi Bansal-Travers; Matthew C Rousu; James F Thrasher; Andrew Hyland; K Michael Cummings
Journal:  Am J Health Behav       Date:  2014-01

7.  A Risk-Continuum Categorization of Product Use Among US Youth Tobacco Users.

Authors:  Sherine El-Toukhy; Kelvin Choi
Journal:  Nicotine Tob Res       Date:  2016-01-13       Impact factor: 4.244

8.  US smokers' reactions to a brief trial of oral nicotine products.

Authors:  Richard J O'Connor; Kaila J Norton; Maansi Bansal-Travers; Martin C Mahoney; K Michael Cummings; Ron Borland
Journal:  Harm Reduct J       Date:  2011-01-10

9.  The scientific foundation for tobacco harm reduction, 2006-2011.

Authors:  Brad Rodu
Journal:  Harm Reduct J       Date:  2011-07-29

10.  Minimising the harm from nicotine use: finding the right regulatory framework.

Authors:  Ron Borland
Journal:  Tob Control       Date:  2013-05       Impact factor: 7.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.